Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) with and without ribavirin
(RBV) for 12 weeks and SOF/VEL FDC for 24 weeks in adults with chronic hepatitis C virus
(HCV) infection and Child-Pugh-Turcotte (CPT) class B cirrhosis.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir